All In Biotech

NDA 020090 · Pfizer

Diflucan

Fluconazole · Oral · Azole Antifungal

Last checked: Nov 19, 2026Latest source record: Feb 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Dec 23, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

259

66 Phase 3, 22 recruiting

FAERS reports

70,762

59,877 serious, 12,605 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 2, 2026.

INDICATIONS AND USAGE Fluconazole is indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida ). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Prophylaxis Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.

Mechanism: Mechanism of Action Fluconazole is a highly selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-α-demethylase. This enzyme functions to convert lanosterol to ergosterol. The subsequent loss of normal sterols correlates with the accumulation of 14-α-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 1993 Original approval · Type 3 - New Dosage Form
2 products under this application
  • DIFLUCAN · FLUCONAZOLE 50MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
  • DIFLUCAN · FLUCONAZOLE 200MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluconazole" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,269
  • off label use4,705
  • pyrexia4,261
  • nausea3,868
  • diarrhoea3,655
  • fatigue3,320
  • pain3,210
  • drug interaction3,089
  • headache2,999
  • pneumonia2,937
  • febrile neutropenia2,741
  • rash2,522

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,081
20051,191
20061,243
20071,184
20081,359
20091,567
20101,650
20112,504
20122,479
20132,100
20142,290
20153,173
20163,829
20173,887
20185,023
20195,586
20205,251
20214,995
20224,531
20234,172
20244,469
20254,315
20262,874

Recalls

1 FDA enforcement reports for this application.

  • Jan 29, 2014 · Class II · Terminated

    Defective Container: Tamper evident ring failures discovered on some bottles.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diflucan (Fluconazole)

2024 spending

$335K

Beneficiaries

206

348 claims

Per beneficiary

$1,627

$23.75 per unit

View as table
YearSpending
2020$544,440
2021$539,499
2022$322,406
2023$229,457
2024$335,102

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,078 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.